Terns Pharmaceuticals, Inc.
TERN
$3.81
-$0.02-0.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.94% | 20.40% | -46.77% | 2.53% | -3.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.79% | 7.86% | -24.85% | 20.69% | 5.34% |
| Operating Income | -7.79% | -7.86% | 24.85% | -20.69% | -5.34% |
| Income Before Tax | -6.93% | -3.76% | 26.34% | -27.22% | -3.76% |
| Income Tax Expenses | -9.28% | -18.37% | 6.90% | -15.28% | 61.67% |
| Earnings from Continuing Operations | -6.86% | -3.71% | 26.28% | -27.05% | -3.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.86% | -3.71% | 26.28% | -27.05% | -3.93% |
| EBIT | -7.79% | -7.86% | 24.85% | -20.69% | -5.34% |
| EBITDA | -7.92% | -7.91% | 24.93% | -20.69% | -5.33% |
| EPS Basic | 13.07% | 17.79% | 32.23% | -21.73% | 2.53% |
| Normalized Basic EPS | 12.99% | 17.77% | 32.28% | -21.91% | 2.70% |
| EPS Diluted | 13.07% | 17.79% | 32.23% | -21.73% | 2.53% |
| Normalized Diluted EPS | 12.99% | 17.77% | 32.28% | -21.91% | 2.70% |
| Average Basic Shares Outstanding | 22.95% | 26.14% | 8.79% | 4.34% | 6.62% |
| Average Diluted Shares Outstanding | 22.95% | 26.14% | 8.79% | 4.34% | 6.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |